Outcome from consecutive ICSI cycles in patients treated with recombinant human LH and those supplemented with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol

References

• Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994;9:188–91
   PubMed Web of Science ®Google Scholar
• Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cel Endocrinol 2001;179:39–46
   PubMed Web of Science ®Google Scholar
• Zeleznik AJ. Follicle selection in primates: “many are called but few are chosen”. Biol Reprod 2001;65:655–9
   PubMed Web of Science ®Google Scholar
• Balasch J, Miró F, Burzaco I, et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod 1995;10:1678–83
   PubMed Web of Science ®Google Scholar
• Balasch J, Fábregues F. Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obstet Gynecol 2002;14:265–74
   PubMed Web of Science ®Google Scholar
• Jacobson A, Marshall JR. Ovulatory response rate with human menopausal gonadotropins of varying FSH-LH ratios. Fertil Steril 1969;20:171–5
   PubMed Web of Science ®Google Scholar
• Louwerens B. The clinical significance of the FSH/LH ratio in gonadotropin preparations of human origin. A review. Acta Obstet Gynecol Scand 1969;48:31–40
   PubMed Web of Science ®Google Scholar
• Hugues JN. Impact of ‘LH activity’ supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review. Hum Reprod 2012;27:232–43
   PubMed Web of Science ®Google Scholar
• Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update 2004;10:453–67
   PubMed Web of Science ®Google Scholar
• Gibreel A, Bhattacharya S. Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics 2010;4:5–17
   PubMedGoogle Scholar
• Balasch J, Fábregues F. LH in the follicula phase: neither too high nor too low. Reprod Biomed Online 2006;12:406–15
   PubMed Web of Science ®Google Scholar
• Giudice E, Crisci C, Altarocca V, O’Brien M. Characterisation of a partially purified human menopausal gonadotropin preparation. J Clin Res 2001;4:27–34
   Google Scholar
• Bosch E. Recombinant human follicular stimulating hormone and recombinant human luteinizing hormone in a 2:1 ratio combination. Pharmacological characteristics and clinical applications. Expert Opin Biol Ther 2010;10:1001–9
   PubMed Web of Science ®Google Scholar
• Pacchiarotti A, Sbracia M, Frega A, et al. Urinary hMG (Menopur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril 2010;94:2467–9
   PubMed Web of Science ®Google Scholar
• Bühler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study. Gynecol Endocrinol 2012;28:345–50
   PubMed Web of Science ®Google Scholar
• Balasch J, Vidal E, Peñarrubia J, et al. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in downregulated women stimulated with recombinant FSH. Hum Reprod 2001;16:1636–43
   PubMed Web of Science ®Google Scholar
• Peñarrubia J, Fábregues F, Creus M, et al. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. Hum Reprod 2003;18:2689–97
   PubMed Web of Science ®Google Scholar
• Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616–24
   PubMed Web of Science ®Google Scholar
• Veeck LL. An atlas for human gametes and conceptuses: an illustrated reference for asssisted reproductive technology. New York: CRC Press-Parthenon Publishers; 1999
   Google Scholar
• Balasch J, Fábregues F, Carmona F, et al. Ovarian luteinizing hormone priming preceding follicle-stimulating hormone stimulation: clinical and endocrine effects in women with long-term hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2009;94:2367–73
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, de Ziegler D, Howles CM, et al. The antral follicle count: practical recommendations for better standardization. Fertil Steril 2010;94:1044–51
   PubMed Web of Science ®Google Scholar
• Peñarrubia J, Peralta S, Fábregues F, et al. Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression. Fertil Steril 2010;94:2590–5
   PubMed Web of Science ®Google Scholar
• Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol 2010;8:112
   PubMed Web of Science ®Google Scholar
• Hill MJ, Levy G, Levens ED. Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature. Reprod Biomed Online 2012;24:261–71
   PubMed Web of Science ®Google Scholar
• Macklon NS, Stouffer RL, Giudice LC, Fauser BCJM. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27:170–207
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa I, Fauser B. The use of GnRH agonist in IVF protocols. 2010. Available from: http://www.IVF-Worldwide.com
   Google Scholar
• Mochtar MH, Van der Veen F, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007;Apr 18:CD005070
   Google Scholar
• Imthurn B, Macas E, Rosselli M, Keller PJ. Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin. Hum Reprod 1996;11:2387–91
   PubMed Web of Science ®Google Scholar
• Out HJ, Mannaerts BM, Driessen SG, Coelingh Bennink HJ. Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies: results from five comparative studies. Hum Reprod Update 1996;2:162–71
   PubMed Web of Science ®Google Scholar
• Ng EH, Lau EY, Yeung WS, Ho PC. HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial. Hum Reprod 2001;16:319–25
   PubMed Web of Science ®Google Scholar
• Balasch J, Peñarrubia J, Fábregues F, et al. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction. Reprod Biomed Online 2003;7:35–42
   PubMedGoogle Scholar
• Tarlatzis B, Tavmergen E, Szamatowicz M, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod 2006;21:90–4
   PubMed Web of Science ®Google Scholar
• Hompes PG, Broekmans FJ, Hoozemans DA, Schats R; FIRM group. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril 2008;89:1685–93
   PubMed Web of Science ®Google Scholar
• Messinis IE, Templeton AA. The importance of follicle-stimulating hormone increase for folliculogenesis. Hum Reprod 1990;5:153–6
   PubMed Web of Science ®Google Scholar
• Lolis DE, Tsolas O, Messinis IE. The follicle-stimulating hormone threshold level for follicle maturation in superovulated cycles. Fertil Steril 1995;63:272–7
   Web of Science ®Google Scholar
• Lambert A, Talbot JA, Anobile CJ, Robertson WR. Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Mol Hum Reprod 1998;4:619–29
   PubMed Web of Science ®Google Scholar
• Fleming R, Rehka P, Deshpande N, et al. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum Reprod 2000;15:1440–5
   PubMed Web of Science ®Google Scholar
• Racowsky C, Orasanu B, Hinrichsen MJ, Ginsburg ES. Embryo quality based on ovulation induction: defining the differences. Reprod Biomed Online 2005;11:22–5
   PubMed Web of Science ®Google Scholar
• Foutouh IA, Khattab S, Mohesn IA, et al. Clinical outcome following stimulation with HMG versus highly purified HMG in patients undergoing ICSI. Reprod Biomed Online 2007;14:145–7
   PubMed Web of Science ®Google Scholar
• Porchet HC, Le Cotonnec JY, Neuteboom B, et al. Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone. J Clin Endocrinol Metab 1995;80:667–73
   PubMed Web of Science ®Google Scholar
• le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril 1998;69:189–94
   PubMed Web of Science ®Google Scholar
• le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. Fertil Steril 1998;69:195–200
   PubMed Web of Science ®Google Scholar
• le Cotonnec JY, Loumaye E, Porchet HC, et al. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril 1998;69:201–9
   PubMed Web of Science ®Google Scholar
• Peinado JA, Molina I, Pla M, et al. Recombinant human luteinizing hormone (rh-LH) as ovulatory stimulus in superovulated doses. J Assist Reprod Genet 1995;12:61–4
   PubMed Web of Science ®Google Scholar
• Grøndahl ML, Borup R, Lee YB, et al. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertil Steril 2009;91:1820–30
   PubMed Web of Science ®Google Scholar
• Ferraretti AP, Gianaroli L, Magli MC, et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertil Steril 2004;82:1521–6
   PubMed Web of Science ®Google Scholar